Pyran Derivatives: Anti-Breast Cancer Activity and Docking Study

Four novel pyran derivatives 1–4 are synthesized and characterized by IR, 1H NMR, HRMS, and single crystal X-ray data. Anticancer activity of the compounds is tested against four human breast cancer cells (HCC1937, HCC70, MDA-MB-436, and BT474) by MTT assay. Molecular docking study supports the biological assay data and suggests that compound 2 has a potential as an anticancer agent.